Discover the journey of Nova Genetica — from its foundation to its growing presence in Nepal's pharmaceutical landscape.
Nova Genetica Pvt. Ltd. was established in 2009 and began operations in 2010. Headquartered in Kathmandu, the company operates its manufacturing facility at Naubise, Dhading.
Over the years, Nova Genetica has focused on reliable medicines, advanced technology, disciplined manufacturing processes, and quality systems designed around patient well-being.
Key milestones that define Nova Genetica's journey and continuing commitment to pharmaceutical quality.
Nova Genetica Pvt. Ltd. was established with a vision to build a modern Nepalese pharmaceutical company driven by quality, innovation, and accessibility.
Pilot batches were initiated for laboratory evaluation and quality assurance, marking the beginning of Nova Genetica’s manufacturing journey.
A state-of-the-art Quality Control and Research & Development (R&D) department was established to create a strong foundation for product quality, consistency, and innovation.
Following marketing approval from Nepal’s Department of Drug Administration (DDA), Nova Genetica officially launched its products across the country.
The year also marked an important milestone in pharmaceutical innovation as Nova introduced Mouth Dissolving Technology in Nepal, bringing a new and convenient dosage form to the domestic market.
Nova continued to challenge conventional product offerings by introducing formulations that had previously been uncommon in Nepal and were largely dominated by imported brands.
The company introduced products such as Diclofenac Mouthwash, Vaginal Pessaries, Anti-Hemorrhoidal Cream, and Enema, expanding access to specialized pharmaceutical formulations within Nepal.
Nova Genetica achieved a major quality milestone by receiving its WHO-GMP Certification, strengthening its commitment to internationally recognized manufacturing standards.
During this period, the company:
Recognizing the growing need for high-quality Cephalosporin products, Nova Genetica established a dedicated Cephalosporin production facility, reinforcing its commitment to specialized and controlled manufacturing.
Through technical knowledge acquired from CKD Corporation, South Korea, Nova developed and manufactured advanced antibiotic combinations including Cefixime + Clavulanic Acid and Cefpodoxime + Clavulanic Acid.
These formulations were successfully introduced to the Nepalese market, marking another significant step in Nova’s journey of pharmaceutical innovation.
With a long-term vision of entering international markets, Nova began upgrading its laboratory infrastructure and manufacturing systems toward PIC/S-aligned standards.
New laboratory equipment was introduced, while production, Quality Control, and R&D teams underwent continuous technical training in Nepal and India, supported by external pharmaceutical experts.
These initiatives formed part of Nova’s growing ambition to become an export-oriented Nepalese pharmaceutical manufacturer, with markets such as Myanmar, Laos, and Africa identified for future expansion.
During this period, Nova also broadened its therapeutic presence with the launch of a dedicated Cardiac & Diabetes Division.
From introducing new pharmaceutical technologies to strengthening manufacturing standards and expanding across therapeutic segments, Nova Genetica’s journey has been shaped by one consistent objective:
To continuously evolve, innovate, and build a Nepalese pharmaceutical company capable of meeting world-class standards.
Building on a decade of growth, Nova Genetica entered its next phase with a stronger focus on nationwide market expansion, portfolio development, and organizational growth.
The company continued expanding its presence across Nepal, strengthening its field operations and making Nova products increasingly accessible to healthcare professionals and patients across the country.
Throughout this period, Nova remained committed to maintaining continuity of pharmaceutical production and supply, while strengthening internal systems to operate effectively in a rapidly changing environment.
Nova was the first pharmaceutical company to obtain license for sanitizers, huge production and distribution of neofresh
The company continued investing in its manufacturing capabilities, Quality Control, R&D, people, and processes, with a growing emphasis on quality systems and long-term institutional development.
This phase marked Nova’s transition from rapid domestic growth toward building a stronger and more structured pharmaceutical organization.
With an increasingly diverse product portfolio and growing nationwide presence, Nova began another phase of modernization focused on quality, technology, systems, and infrastructure.
Manufacturing and laboratory capabilities were progressively strengthened, while greater emphasis was placed on Quality Management Systems, documentation, process controls, training, and continuous improvement.
The objective was clear: to build an organization capable of meeting increasingly stringent pharmaceutical standards.
Nova entered a new phase of organizational development with a renewed focus on professional management, data-driven operations, stronger field execution, and continuous improvement across manufacturing and commercial functions.
By this stage, Nova had developed a broad manufacturing capability spanning tablets, capsules, dry syrups, pessaries, creams, ointments, lotions, gels, syrups, suspensions, drops, solutions, oral rinses, and enemas.
The company continued strengthening its nationwide presence while preparing itself for the next chapter of growth.
Having built a strong foundation in Nepal, Nova Genetica began looking beyond its domestic journey.
A comprehensive initiative was undertaken to progressively upgrade the manufacturing facility, infrastructure, laboratory capabilities, documentation, Quality Management Systems, data integrity, and operational processes toward more advanced international and export-ready standards.
Nova also began actively exploring international partnerships, contract manufacturing opportunities, technology collaborations, and potential export markets across Asia, Africa, and other emerging markets.
At the same time, the company continued investing in new products, technologies, people, and systems to strengthen its position within Nepal.
From a vision established in 2009 to a growing pharmaceutical organization with nationwide operations, diverse manufacturing capabilities, and international ambitions, Nova Genetica has continued to evolve with every milestone.
Today, our focus extends beyond growth alone. We are working toward building an organization defined by quality, innovation, technology, strong systems, and global competitiveness.
Our next chapter is driven by a simple ambition:
To take pharmaceutical excellence from Nepal to the world.
Quality systems and certified processes support safe, reliable pharmaceutical manufacturing.
Advanced technology and disciplined processes support the development and manufacture of medicines.
Nova Genetica's work is guided by the goal of contributing to better and more affordable healthcare.